Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Cardinal Health Inc    CAH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Cardinal to Buy Home-Medical Firm AssuraMed for $2.07 Billion

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2013 | 02:26pm CET

By Jon Kamp

--Cardinal paying $2.07 billion to tap growing home-care market

--Deal adds to Cardinal's existing medical-supplies franchise

--Cardinal sees earnings benefit from fast-growing AssuraMed

Drug wholesaler and medical-products company Cardinal Health Inc. (>> Cardinal Health, Inc.) said Thursday it will acquire closely held medical-supplier AssuraMed for $2.07 billion to reach into a growing home-care market.

AssuraMed currently serves more than one million patients nationally with more than 30,000 products, including supplies for respiratory issues, incontinence and diabetes. The company bought Invacare Corp.'s (>> Invacare Corporation) domestic medical-supplies business for $150 million last month. Including that business, Cardinal Heath said AssuraMed had 2012 revenue of $1 billion.

Cardinal cited government data showing this market growing sales at a 7%-and-rising clip, but said AssuraMed has historically grown at more than twice that pace. Though AssuraMed will represent only about 1% of total Cardinal sales, it has higher profit margins, and Cardinal expects an earnings benefit.

Dublin, Ohio's Cardinal gets most of its sales from a pharmaceutical business that includes drug distribution. Cardinal also has a medical segment that distributes an array of medical, surgical and lab products, but is focused today on hospitals and other professional customers.

The AssuraMed deal will extend Cardinal into growing home-care market fueled by aging baby boomers and health payers--from the government to private insurers--looking for cost effective ways to manage patients with chronic illness or on-the-mend from accidents and surgery.

"The general gravitational pull is toward more care moving toward the home," said George Barrett, Cardinal's chairman and chief executive, in an interview.

Cardinal shares rose 2.1% to $46.38 in recent trading. They are up nearly 13% so far this year.

Mr. Barrett believes the home-health business will help Cardinal's relationship with existing customers, since the health system is shifting toward rewarding health providers for patient outcomes, rather than the volume of service provided. This can mean caregivers taking on more responsibility for patients as they move from hospitals to rehabilitation centers or their own homes.

The deal "connects to the dialogue that we're having with our partners," Mr. Barrett said in an interview. It "makes us a more relevant strategic partner to them."

Cardinal said AssuraMed leads a fragmented, roughly $16 billion market for the products it supplies. The company is split into two main businesses: a wholesale distributor that sends products to commercial customers, such as home medical-equipment suppliers, and another business that ships directly to patients' homes.

Cardinal expects the deal to add two cents to three cents a share to its fiscal 2013 adjusted earnings, assuming the deal closes by early April. The company also estimates its will boost fiscal 2014 adjusted earnings by at least 18 cents a share.

Additionally, Cardinal expects at least $50 million in deal-related savings by 2016, and for growing savings thereafter.

Cardinal is financing the deal with $1.3 billion in new senior, unsecured notes and cash. Debt-ratings firm Fitch Ratings called the transaction "strategically sound" while saying it should bolster Cardinal's intermediate-term growth outlook.

The medical-products deal comes as Cardinal faces some big questions in its drug wholesale business. The company is working to try and keep its two biggest customers, the drugstore chains CVS Caremark Corp. (>> CVS Caremark Corporation) and Walgreen Co. (>> Walgreen Company), after existing contracts with both companies end this summer.

--Melodie Warner contributed to this article.

Write to Jon Kamp at jon.kamp@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARDINAL HEALTH INC
02/25 CARDINAL HEALTH : Drug firms want case moved to fed court
02/25 CARDINAL HEALTH : Cah) Shares Bought by Tredje Ap Fonden
02/24 CARDINAL HEALTH : Survey Finds Hospital Staff Report Better Supply Chain Managem..
02/15 CARDINAL HEALTH : Survey Finds Hospital Staff Report Better Supply Chain Managem..
02/15 Fibrin Sealant Market 2017 - Adhezion Biomedical, Hemostasis, Arch Therapeuti..
02/14 INSIDER TRADING ACTIVITY CARDINAL HE : CAH) – Chairman Sold 217,994 shares..
02/14 CARDINAL HEALTH : City of Welch suing drug companies over opioids
02/09 CARDINAL HEALTH : profits remain flat but CEO sees potential relief in generic p..
02/07DJCARDINAL HEALTH : Again Trims 2017 Profit Forecast
02/07 CARDINAL HEALTH : beats 2Q profit forecasts
More news
Sector news : Drug Retailers - NEC
02/16DJRetail CEOs Meet With Trump Over Border Tax Concerns -- Update
02/15DJRetail CEOs Meet With Trump Over Border Tax Concerns
02/14DJEXPRESS SCRIPTS : Revenue Falls
02/14 Exclusive - Trump to meet with retail CEOs on taxes, infrastructure
02/09DJCVS HEALTH : Profit Rises, Helped by Pharmacy Strength -- Update
More sector news : Drug Retailers - NEC
News from SeekingAlpha
02/23 Can 20 Financial Ratios Measure A Company's Moat Just Like Morningstar? Updat..
02/22 Buying McKesson At A 10% Yield
02/16 Tracking Seth Klarman's Baupost Group Holdings - Q4 2016 Update
02/15 THE MNM PORTFOLIO, JAN. 2017 : Ep. 23 - Introducing The MnM 401K!
02/13 MY 86 STOCK PORTFOLIO EVALUATION : Is The Price Right To Buy Using A 3 Category ..
Advertisement
Financials ($)
Sales 2017 130 915 M
EBIT 2017 2 872 M
Net income 2017 1 377 M
Debt 2017 2 904 M
Yield 2017 2,18%
P/E ratio 2017 18,65
P/E ratio 2018 16,02
EV / Sales 2017 0,22x
EV / Sales 2018 0,20x
Capitalization 25 911 M
More Financials
Chart CARDINAL HEALTH INC
Duration : Period :
Cardinal Health Inc Technical Analysis Chart | CAH | US14149Y1082 | 4-Traders
Full-screen chart
Technical analysis trends CARDINAL HEALTH INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 82,0 $
Spread / Average Target -0,17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George S. Barrett Chairman & Chief Executive Officer
Michael C. Kaufmann Chief Financial Officer
Patricia B. Morrison Chief Information Officer & EVP
Calvin Ramarro Darden Independent Director
Gregory B. Kenny Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDINAL HEALTH INC14.13%25 911
WALGREENS BOOTS ALLIAN..5.86%94 567
CVS HEALTH CORP3.26%83 574
EXPRESS SCRIPTS HOLDIN..4.01%43 339
MCKESSON CORPORATION7.40%31 988
AMERISOURCEBERGEN CORP..17.87%20 024
More Results